Dose Assessment of Melatonin in Sepsis Trial

• Status: Withdrawn
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

DAMSEL 2 is a pilot Phase II study in patients with sepsis. Stage 1 will assess the pharmacokinetics of melatonin and its major metabolite after a single dose of 50 or 100mg exogenous melatonin in two small groups of patients with sepsis in order to make dosing and dosing interval decisions for Stage 2.

Stage 2 is a double blind randomised controlled trial of melatonin in patients with sepsis at the dose and dosing interval decided after Stage 1. Measurements of melatonin and its major metabolite, and an array of biomarkers of inflammation and oxidative stress will be made, plus transcriptome (mRNA) analysis. This study will inform a planned larger phase II trial.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aberdeen
• Treatments: Melatonin

Criteria

Inclusion Criteria:

Adult patients (16 years or over) on the ICU at Aberdeen Royal Infirmary with sepsis due to community acquired pneumonia who are within 24h of fulfilling the criteria for sepsis with clinical suspicion of pneumonia and the presence of chest X-ray changes consistent with pneumonia will be recruited. The criteria for sepsis are:

• clinical suspicion or evidence of acute infection

• systemic inflammatory response syndrome, defined by two or more of the following:

1. Core temperature <36 or >38°C;

2. tachycardia: heart rate > 90 beats/min;

3. tachypnoea: respiratory rate > 20 breaths/min or ventilated;

4. leucocyte count >12 x 109/L or <4 x 109/L.

Exclusion Criteria:

• <16 years old,

• have a life expectancy <24h,

• have metastatic cancer or immunosuppression,

• are receiving steroids (>20mg/d prednisolone or equivalent, used regularly for >2 weeks prior to ICU admission)

• women of child bearing potential without a negative pregnancy test or a history of surgical sterilization.

• patients receiving fluvoxamine or nifedipine,

• have overt hepatic failure

• unable to tolerate oral medication

• known to be hypersensitive to trial medication and/or excipients